Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutic (SRPT) Eteplirsen NDA Filing on Track for Year-End, Needham & Company
August 7, 2014 11:55 AM EDTNeedham & Company analyst Chad Messer, Ph.D reiterated a Buy rating and $52 price target on Sarepta Therapeutic (NASDAQ: SRPT) following Q2 results, noting Eteplirsen NDA filing is on track for year end.
Messer commented, "Management provided a detailed clinical and regulatory update on eteplirsen and follow-on exon skipping drugs for DMD on Sarepta's 2Q:14 earnings call. The bottom line is that all relevant activities are progressing well and the company remains on track to filing an... More
Sarepta Therapeutics (SRPT) CEO Chris Garabedian Speaks on CNBC
August 5, 2014 5:50 PM EDTSarepta Therapeutics (NASDAQ: SRPT) was active Tuesday following comment from CEO Chris Garabedian on CNBC.
... MoreSarepta Therapeutics (SRPT) Sees Upside
August 5, 2014 12:57 PM EDTSarepta Therapeutics (NASDAQ: SRPT) sees upside on volume. Shares up 2.9%.
... More